SAN DIEGO , Dec. 21, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc.(HALO) today announced a global collaboration and license agreement with Eli Lilly and Company(LLY) to develop and commercialize products combining proprietary Lilly compounds with Halozyme's ENHANZE™ platform.
Under the terms of the agreement, Halozyme will receive an initial $25 million payment, followed by milestone payments of up to $160 million for each of up to five collaboration targets valued at up to $800 million. These payments are subject to Lilly's achievement of specified development, regulatory and sales-based milestones. In addition, Lilly will pay Halozyme mid-single digit royalties if products under the collaboration are commercialized
Starting to think about what might be the specific candidates here. Of course Lilly is a major company in insulin but I am not sure that would be a target. Perhaps the oncology area where Lilly has products like
Cyramza which is a one hour infusion delivery. Anyone else have ideas?